Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFECT I: Epanova versus placebo and fenofibrate for liver fat reduction in overweight hypertriglyceridemic adults with non-alcoholic fatty liver disease
2014-003637-26Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia comparing Epanova, Placebo and Lipanthyl (3 arms). Primary endpoint: Change in liver fat content. Started Jan 2015; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acidfenofibrate
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hypertriglyceridemia
Beyond the preview
Go deeper on 2014-003637-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003637-26.